Item
7.01 Regulation FD Disclosure.
On
November 5, 2007, Aeolus Pharmaceuticals, Inc. (“Aeolus”) provided an update on
its drug development program and on November 7, 2007, Aeolus reported results
of
a pre-clinical study of AEOL 10150 for the treatment of mustard gas
exposure.
Copies
of
the press releases issued by Aeolus on November 5, 2007 and November 7, 2007
announcing these events are attached as Exhibit 99.1 and 99.2, respectively,
to
this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
|
(c)
|
Exhibits
|
| Exhbit 99.1 | Press Release dated November 5, 2007 |
| Exhibit 99.2 | Press Release dated November 7, 2007 |
SIGNATURE
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this Report
to
be signed on its behalf by the undersigned thereunto duly
authorized.
AEOLUS
PHARMACEUTICALS,
INC.
Date: November
7, 2007
/s/
Michael P.
McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary